Genmab A/S (NASDAQ:GMAB) Prioritizes Late-Stage Assets, Tightening Near-Term Focus
![]() |
Genmab shifts capital and clinical effort toward its highest-impact late-stage programs while trimming lower-priority development, creating a near-term operational concentration. Strong cash generation and margins anchor valuation even as technical momentum shows recent waning. |










